UNSPSC 85722679: Fusion of left tarsal joint with synthetic substitute, percutaneous endoscopic approach

This classification denotes the group of activities that yields a surgical intervention or procedure to fusion of left tarsal joint with synthetic substitute, percutaneous endoscopic approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0SGJ4JZ

UNSPSC 85722679 Fusion of left tarsal joint with synthetic substitute, percutaneous endoscopic approach is a Commodity code that does not reflect the work state and local governments are actually buying under this tag. The recent opportunities posted under this code span occupational health surveillance, pharmacy benefit management, temporary clinical staffing, independent disability medical evaluations, and surgical care network management — none of which are orthopedic surgical procedures or involve tarsal joint fusion. The code appears to have been misapplied by issuing bodies to healthcare services and benefits administration solicitations that have no connection to the procedure named in the code's formal title.

Activity comes from a mix of county health systems, county commissioners' offices, state departments, and municipal retirement boards across Arizona, California, Florida, and Washington. The Washington State Department of Transportation (on behalf of Washington State Ferries) posted an RFP for occupational medical surveillance services with a response deadline of October 9, 2026; the City of Phoenix Retirement Office posted an RFP for independent medical evaluation services supporting disability benefit determinations with a response deadline of October 16, 2026; the City of Long Beach posted an RFP for surgical care carve-out and Center of Excellence networks with a response deadline of October 7, 2026; and the County of Santa Clara Health System posted an RFQ for temporary health professional staffing across multiple ancillary clinical categories with a response deadline of October 7, 2026. Because the code's label does not match the procurement activity tagged under it, the code itself offers limited signal for business development targeting. Vendors should treat this code as misclassified and verify actual scope against individual opportunities rather than relying on the code's formal procedure description.